Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316842 | 0.87 | LMNA (0.56) | MTNR1AKDM4EALDH1A1POLBABCB1 | |
| SCHEMBL16703460 | 0.85 | MRGPRX1 (0.52) | MTNR1AKDM4EALDH1A1MRGPRX1MEN1 | |
| SCHEMBL26607683 | 0.84 | MTNR1A (0.52) | MTNR1AKDM4EHSD17B10ALDH1A1MRGPRX1 | |
| SCHEMBL30634364 | 0.84 | MTNR1A (0.52) | MTNR1AKDM4EHSD17B10ALDH1A1MRGPRX1 | |
| SCHEMBL7431136 | 0.80 | MRGPRX1 (0.48) | MTNR1AKDM4EALDH1A1MRGPRX1POLB | |
| SCHEMBL4864450 | 0.80 | ALDH1A1 (0.49) | MTNR1AKDM4EALDH1A1MRGPRX1POLB | |
| SCHEMBL30317135 | 0.79 | MRGPRX1 (0.46) | MTNR1AKDM4EALDH1A1MRGPRX1ABCB1 | |
| SCHEMBL7949833 | 0.79 | MRGPRX1 (0.46) | MTNR1AKDM4EALDH1A1MRGPRX1ABCB1 | |
| SCHEMBL10813137 | 0.79 | MTNR1B (0.55) | MTNR1AKDM4EHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL10800257 | 0.79 | MRGPRX1 (0.47) | MTNR1AKDM4EALDH1A1MRGPRX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | BIOSYNTHIS (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4321651-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXO ESTER | Biosynthis (FR) | 2024-02-14 | — | — | EP | claimed |
| EP-4387582-A1 | METHOD FOR INHIBITING CRYSTALLISATION | Biosynthis (FR) | 2024-06-26 | — | — | EP | disclosed |
| CN-112203633-B | Cosmetic vehicle comprising a C8-C10 alkane and a C > =11 alkane | 碧昂赛恩斯公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240158719-A1 | METHOD FOR FRACTIONATING A SHEA EXTRACT | BIOSYNTHIS (FR) | 2024-05-16 | — | — | US | disclosed |
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | BIOSYNTHIS (FR) | 2024-05-02 | — | — | US | disclosed |
| CN-117940101-A | Method for inhibiting crystallization | 碧昂赛恩斯公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4321651-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXO ESTER | Biosynthis (FR) | 2024-02-14 | — | — | EP | disclosed |
| EP-4305134-A1 | METHOD OF FRACTIONATING A SHEA EXTRACT | Biosynthis (FR) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023194511-A1 | COMPOSITION FOR THE COSMETIC TREATMENT OF KERATIN FIBERS | BIOSYNTHIS (FR) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023166198-A1 | EYE MAKEUP COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES | BIOSYNTHIS (FR) | 2023-09-07 | — | — | WO | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1506178-A4 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | MTNR1A 100/4885KDM4E 1161/4885HSD17B10 116/4885 |
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | ALKBH2, ABHD12, FAAH2 | MTNR1A 1550/4885KDM4E 2753/4885HSD17B10 568/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | MTNR1A 109/4885KDM4E 1539/4885HSD17B10 133/4885 |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | MTNR1A 93/4885KDM4E 1108/4885HSD17B10 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.